1. Home
  2. SIEB vs AGEN Comparison

SIEB vs AGEN Comparison

Compare SIEB & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Siebert Financial Corp.

SIEB

Siebert Financial Corp.

HOLD

Current Price

$1.83

Market Cap

164.1M

Sector

Finance

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.46

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SIEB
AGEN
Founded
1886
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
164.1M
147.4M
IPO Year
1996
1999

Fundamental Metrics

Financial Performance
Metric
SIEB
AGEN
Price
$1.83
$3.46
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
16.6K
889.8K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.00
EPS
0.13
1.02
Revenue
$94,202,000.00
$42,877,086.00
Revenue This Year
N/A
$107.63
Revenue Next Year
N/A
N/A
P/E Ratio
$13.85
$3.48
Revenue Growth
12.28
89.95
52 Week Low
$1.68
$2.71
52 Week High
$5.53
$7.34

Technical Indicators

Market Signals
Indicator
SIEB
AGEN
Relative Strength Index (RSI) 44.34 42.58
Support Level $1.68 $2.91
Resistance Level $1.97 $4.72
Average True Range (ATR) 0.08 0.25
MACD 0.01 -0.07
Stochastic Oscillator 25.08 22.43

Price Performance

Historical Comparison
SIEB
AGEN

About SIEB Siebert Financial Corp.

Siebert Financial Corp is a diversified financial services firm and provides a full range of brokerage and financial advisory services including securities brokerage, investment advisory and insurance offerings, and corporate stock plan administration solutions. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: